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ABSTRACT 
 
 
 
MOUSE MODEL OF AORTIC ARTERIAL INJURY AND DENUDATION AND 
POLYMERIC STENT DELIVERY IN MICE 
 
 
Ashkon C. Nehzati 
 
 
More than 385,000 people die from coronary heart disease (CHD) annually and treatment 
costs $108.9 billion each year including the cost of health care services, medications, and 
lost productivity. CHD decreases heart function by limiting oxygen and nutrient transport 
carried through the coronary arteries. A complete block to the coronary arteries causes a 
myocardial infarction in response to an elimination of blood supply to cardiomyocytes.  
Partial occlusion results in insufficient blood supply to cardiomyocytes, producing 
myocardial ischemia and angina, which are usually treated with intravascular stents 
deployed percutaneously, before myocardial infarction occurs. Stents are the most 
common ways to expand occluded vessels to treat CHD, with over 1 million stents placed 
in coronary arteries each year. Unfortunately restenosis, the narrowing of vessels due to 
endothelial damage and inflammation, is a common complication found after stenting 
with rates for bare metal stents reported to be between 16% and 44% or about 160,000 to 
440,000 patients. Even with the recent advancement in stent technology and the 
introduction of drug eluting stents (DES), restenosis has continued to be a significant 
problem associated with stenting. DES restenosis is estimated to occur in 200,000 
patients in the United States. It has recently been found that DES may also put patients at 
risk for late-stent thrombosis due to the delayed healing effects of the antiproliferative 
coating. With medicine growing at a rapid pace, new stent designs are researched to 
address new complications such as late-stent thrombosis. These newer designs need 
newer animal models to better understand the response of the vascular wall to newer stent 
technologies. The purpose of this study was to develop a mouse model of neointimal 
hyperplasia in response to aortic endothelial denudation. This model would allow for 
examination of the neointimal hyperplasia and endothelialization responses to next 
generation intravascular technologies, such as polymeric stents.  
 
 
 
 
 
 
 
 
Keywords: Stents, Neointimal Hyperplasia, Restenosis, Late-Stent Thrombosis, Coronary 
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Chapter 1:  INTRODUCTION 
 
CORONARY HEART DISEASE 
 
Overview 
  
Coronary heart disease (CHD) is an ischemic disease caused by the narrowing or 
blockage of the coronary arteries due to atherosclerosis. The buildup of plaque on the 
inner walls of the arteries physically restricts blood flow to the myocardium. Without a 
sufficient supply of blood, the heart is unable to receive vital nutrients as well as a 
consistent flow of oxygen, inducing myocardial ischemia, which presents as angina to the 
patient. If the coronary artery becomes completely occluded, a myocardial infarct will 
occur, and cardiomyocytes will necrose. Over time, CHD can cause enlargement of the 
left ventricle, which can lead to heart failure and arrhythmias. 
 CHD is the most common type of heart disease and is the number one cause of 
death for both men and women in the United States. More than 385,000 people die from 
CHD annually and treatment costs $108.9 billion each year, including the cost of health 
care services, medications, and lost productivity. Undiagnosed, CHD in sedentary 
patients can lead to chest pain and myocardial infarction. Every year about 715,000 
Americans have a myocardial infarction and in a 2005 survey, only 27% of the 
individuals were aware of all major symptoms and to call emergency response during a 
heart attack [1].  
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Figure 1 – Atherosclerosis in Coronary Arteries. B, healthy coronary artery with normal blood flow. 
C, diseased coronary artery with plaque buildup which leads to abnormal blood flow [2]. 
  
The major risk factors for CHD include family history of the disease, being of 
male sex, African-American lineage, and advanced age. Other risk factors include 
dyslipidemia, smoking, diabetes, obesity, hypertension, stress, poor diet, physical 
inactivity, and excessive alcohol use. 
Atherosclerosis, which is characterized by plaque formation in conduit vessels, is 
the cause of CHD. Atherosclerosis pathology is hypothesized to be caused by endothelial 
injury and inflammation which can often lead to the formation of atheromas. Risk factors 
for atherogenesis can further aggravate the process leading to atherosclerotic plaque 
accumulation. This plaque accumulation can restrict blood flow to the heart and 
eventually result in infarcted cardiac tissue.  
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Atherogenesis 
 
Atherogenesis is the process that leads to the formation of atherosclerotic plaques. 
Atherogenesis begins at bifurcations in response to turbulent shear stress by recruiting 
inflammatory cells to the sub-endothelial space. This leads to unresolved inflammation 
and a positive feedback mechanism which further aggravates the process. Endothelial 
activation caused by inflammation induces the separation of endothelial cell junctions, 
adhesion molecule presentation (e.g. VCAMs), and the secretion of chemokines (e.g.  
MCP-1) to activate adhered monocytes. Activated monocytes extravasate through 
endothelial cell gaps and become as macrophages under the influence of Granulocyte-
macrophage colony stimulating factor (GM-CSF). In addition to leukocytes, plasma 
components such as LDL also extravasate into the sub-endothelial. Extravasated LDL is 
oxidized by macrophage-derived reactive oxygen species, and oxLDL is phagocytosed by 
the macrophages. Proinflammatory cytokines are released following oxLDL 
phagocytosis, further activating macrophages and the endothelium. This aggravation 
causes the release of vasoconstrictors, coagulation factors, and smooth muscle mitogens 
that promote cell proliferation and migration into the sub-endothelial space, eventually 
forming a neointima (Figure 2). While this process occurs naturally in the body, it can 
also occur with treatment of atherosclerotic plaques after stent deployment. 
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Figure 2 – Atherogenesis. The mechanistic etiology of atherogenesis from the cellular perspective [3]. 
 
Current Treatment for CHD 
 
Catheter-based therapies are used as an alternative to bypass surgery for CHD 
treatment due to its minimally invasive nature. The development of catheter-based 
therapies began with balloon angioplasty, where plaque-occluded vessels were expanded. 
The balloon angioplasty procedure deploys bare metal stents and addresses the poor 
expansion reliability. Unfortunately, 3 years after bare metal stent implantation, 53% of 
patients experienced in-stent restenosis (ISR), a phenomena in which smooth muscle cell 
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proliferation results in re-occlusion of the artery [4] . Restenosis was addressed by 
coating bare metal stents with antiproliferative drugs that slowly elute over time. DES 
elute antiproliferative agents to delay the restenosis response, but can undergo early-stent 
thrombosis as soon as 30 days or late-stent thrombosis even years after implantation. The 
mechanism for late-stent thrombosis is due to delayed healing by the drug on the stent 
[5]. With further research, biomaterial design in stents will improve drug and 
physiological interactions to help increase safety and efficacy (Figure 3). 
 
Figure 3 - Stent Material Comparison. A stent is implanted by balloon angioplasty, which expands the 
stent into its optimal diameter (left panel). The bare metal stent (top middle) undergoes restenosis while 
the drug eluting stent (bottom middle) undergoes late-stage thrombosis. Both of these are problems that 
stenting should prevent. The bioabsorbable polymer stent (right panel) reduces the risk of restenosis and 
returns normal vessel function by dissolving into the blood stream [6]. 
 
As knowledge of stents and stent effects continue to grow, stent design will evolve to 
address the various complications reported over time. This evolution will lead to more 
sophisticated mechanisms used to manipulate the biologic response to stent implantation. 
DES today manipulate known biological responses with an antiproliferative. A better 
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understanding of the underlying biology is needed to prevent proliferation of or recruit a 
single cell type. To achieve this, a more sophisticated animal model will allow the 
evaluation of the role of single proteins with knock-out mice or disease-like states with 
specific animal models such as Apo -/- or non-obese diabetic (NOD) mice. 
 
STENT USE AND ROLE IN CHD 
 
Testing 
 
Animal models used for stenting are restricted due to limited number of animals 
with comparable human vasculature. Typical models include pigs and rabbits with the 
porcine model widely accepted for the final stages of pre-clinical studies, due to the 
geometric similarities to the human heart and coronary vasculature. The downside to 
these animal models is that they develop very few to no atherosclerotic lesions, even with 
a high-fat “western diet” [7]. As a solution, mice are widely used for early preclinical 
research with the ability to easily manipulate genetics while being affordable. Current 
genetically-modified mice for modeling CHD are ApoE -/- and LDL receptor -/- mice that 
are susceptible to atherosclerosis and plaque development in turbulent flow areas (aortic 
arch and abdominal aorta).  
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OBJECTIVE 
  
The intent of this study was to better understand the neointimal hyperplasia 
response to intravascular stents, which are the most commonly used strategy to re-open 
occluded coronary arteries in human patients. In previous studies, a neointima was 
formed in response to endothelial damage caused by stenting in mice [8]. In a similar 
fashion, comparable stent injury was reproduced by catheterization of the abdominal 
aorta. 
 
Objective: Denude the abdominal aortic endothelium using an injury catheter to 
induce neointima formation. The objective was to validate previous research and 
to optimize the protocol for denuding the abdominal aorta.  
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Chapter 2:  METHODS 
 
Animal Housing and Care 
 
Seven- to 9-week-old male C57Bl/6 mice from Taconic Farms were used for all 
experiments according to approved protocols by the Cal Poly State University 
Institutional Animal Care and Use Committee (IACUC). Mice were housed at the 
University Vivarium in temperature-controlled rooms in microisolator cages. The 
following enrichment items were provided: a “mouse house”, nesting material, and a 
plastic tube. Mice were monitored daily, given water and rodent chow ad libitum, and 
maintained on a 12 hour light/dark cycle (LD 12:12). Cages were changed weekly using 
aseptic technique. 
 
 
Aortic Endothelial Denudation Protocol 
  
An induction chamber with 5% isoflurane in oxygen flowing at ~3 l·min-1 was 
used to anesthetize the mouse. The mouse was then weighed and transferred to a 
preparatory bench where anesthesia was reduced to ~1-3% isoflurane in oxygen flowing 
at 0.5-1.0 l·min-1. Hindlimb hair was removed with clippers and depilatory cream before 
placing the animal supine on a heated surgical stage under a dissection scope. Body 
temperature was kept at ~35° C by a heat pad controlled with a rectal thermistor probe.  
 A small incision was made on the middle, medial aspect of the left hindlimb, 
directly over the femoral neurovascular bundle, and extended proximally to the 
abdominal wall. The area was continually irrigated with phosphate buffered saline (PBS) 
throughout the procedure to prevent desiccation. Connective tissue was blunt dissected 
while a heat cautery was used to remove the epigastric fat pad and a majority of the 
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epigastric neurovascular bundle. The superficial femoral artery was separated from its 
vein and nerve pair, and arteriotomy performed just upstream to the profunda femoris. 
The catheter was inserted into the femoral artery just proximal to the profunda femoris 
branch (Figure 4) and advanced into the abdominal aorta to denude the endothelium. 
Following aortic endothelial denudation, the catheter was partially retracted and 100 
I.U./mL of heparinized saline was injected through the catheter followed by 50 µL of 40 
mg/mL Evans blue dye.  
After the dye circulated, the animal was perfuse fixed with 4% paraformaldehyde 
(PFA). For the perfusion fixation procedure, a thoracotomy was performed to expose the 
heart. The left ventricle was then catheterized and connected to a syringe pump for the 
infusion of PBS following by PFA. An incision was made in the right atrium for solution 
drainage; for a detailed description of the surgical procedure refer to the Appendix. 
 
Figure 4 – Catheterization Procedure Diagram. Illustration of the aortic endothelial denudation 
protocol procedure. 
aorta 
catheter direction 
arteriotomy site 
femoral artery 
kidney 
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Imaging Analysis 
 
Infinity imaging software (Lumenera) was used to capture images and ImageJ 
was used to add scale bars. ImageJ was calibrated using a stage micrometer scale at the 
appropriate magnification. 
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Chapter 3:  RESULTS 
 
The results demonstrate a progression of adjustments made to the protocol while using 
the injury catheter. Figure 5 illustrates a poor Evans Blue and PBS perfusion in the 
abdominal aorta, where the dye was injected into the left ventricle of the heart after 
denudation. Modification to the Evans Blue injection is reflected in Figures 6-8 where the 
dye was introduced through the injury catheter following endothelial denudation. 
 
 
Figure 5 – Poor Evans Blue Stain and Perfusion Fixation of Abdominal Aorta. Evans Blue stain is 
too dark due to poor perfusion fixation. 
aorta 
adipose 
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Figure 6 – Ineffective Evans Blue Stain and Denudation of Abdominal Aorta. Blue staining is 
inconsistent throughout aorta. More damage near iliac bifurcation (darker Evans Blue) due to difficulties 
advancing injury catheter. 
aorta 
severe denudation 
renal artery 
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Figure 7 – Evans Blue Stain with Ineffective Denudation of Abdominal Aorta. Denudation of aorta 
can be seen distal the left renal artery and needed to be more proximal. 
renal artery 
ineffective denudation 
aorta 
 Figure 8 – Successful Evans Blue 
vessel indicates where endothelial denudation has occurred.
renal artery (clear) (3) – Upper a
iliac (clear) (6) - Left iliac (blue)
 
Figure 8 shows an image of 
dye, indicating successful endothelial denudation. 
confirm denudation and works by staining 
membrane of the vessel in areas where the endothelium is damaged
 
 
(1)
15 
Stain and Denudation of Abdominal Aorta. The blue staining of the 
 (1) - Right renal artery (clear) (2) 
bdominal aorta (clear) (4) – Lower abdominal aorta (blue) 
.  
a specimen’s dissected aorta stained with Evans Blue 
The Evans Blue dye was used to 
albumin which adheres to the 
. 
 
aorta 
effective denudation 
 
(2) 
(3) 
(5) 
(6) 
(4) 
 
- Left 
(5) - Right 
basement 
16 
 
Chapter 4:  DISCUSSION 
 
CHD decreases heart function and blood flow through the coronary arteries due to 
atherosclerotic plaque buildup, which is commonly treated by stenting. New types of 
stent designs yield new challenges to solve, like the advent of DES and problems with 
late-stent thrombosis. To address this, we need additional research models to assist 
understanding the responses of the vascular wall to stent implantation. This mouse model 
can serve as the foundation to build upon and to help with the design of newer research 
models. 
 
Success of the Protocol Development 
 The developed protocol was demonstrated successfully with the refinement of the 
surgical procedure to produce endothelial denudation (Figure 8). The injury catheter was 
advanced through the left iliac and into the abdominal aorta to the left renal artery. Due to 
the damage, the basement membrane was exposed, which allows the Evans Blue to stain 
the tissue by binding to the localized albumin. In the clear areas, the basement membrane 
is not exposed, which does not allow albumin to adhere, allowing the vessel to remain 
unstained. 
  
Challenges and Improvements 
Initial experiments revealed difficulty with inserting the injury catheter into the 
femoral artery. This was due to the device and vessel diameter being similar in size. To 
overcome this challenge, a smaller diameter catheter was used while learning how to 
properly perform the arteriotomy and gradually increased to the required catheter size to 
denude the vessel. The purpose of the larger catheter size was twofold. The larger size 
17 
 
allowed for easier endothelial denudation without tearing, as well as a vehicle for 
deployment and future testing of experimental polymeric stents.  
Later experiments were difficult due to tactile unfamiliarity with vessel anatomy 
and blind catheterization with the injury catheter. If the vessel tore at the arteriotomy site 
during an experiment, the mouse was used to practice perfusion fixation. If the vessel 
perforated in the abdominal region, a practice dissection of the abdominal aorta was 
performed. Utilization of the mouse in failed attempted procedures proved helpful to gain 
more experience in mastering other areas of the protocol. After many experiments, 
confidence with tactile feedback grew along with technical skill. Another challenge 
included poor Evans Blue dye perfusion and blood coagulation during perfusion fixation. 
This was addressed with the addition of polyethylene (PE-100) tubing joining the injury 
catheter to a Luer-Lok mechanism (Figure 9 in Appendix). It is important to note that 
there should be sufficient slack available in the tubing so that the Luer-Lok will not catch 
onto the surgical stage. Also, more slack allows for more tactile feedback from the 
catheter due to the weight distribution over a longer length of the tubing preventing it 
from “pulling” the catheter as much.   
Learning the Evans Blue staining protocol revealed inconsistencies with the acute 
denudation experiment completed before. A heterogeneous denudation pattern was 
observed throughout the vessel where the catheter traveled.  Improvements made in the 
protocol involved the twisting movement of the catheter during retraction. This increased 
the amount of damage and homogeneity observed by the Evans Blue stain, particularly 
inferior to the left renal artery. 
 
18 
 
Future Work 
 This optimized protocol will be used in future experiments which will include a 
chronic 28-day study to determine if the formation of a neointima occurs in the denuded 
regions of the abdominal aorta. We are interested in assessing neointimal formation in 
response to injury and/or bioresorbable stent implantation. Neointima formation is 
clinically caused by the endothelial damage left by stent implantation. This damage 
causes smooth muscle cell proliferation into the intima of the artery. The intimal 
thickening causes the artery to undergo restenosis where the vessel wall grows around the 
stent struts, occluding a majority of the blood flow through the vessel. Therefore 
prevention of this neointima is key to solving the issues plaguing stent and angioplasty 
usage. In the future, this model can be used to characterize gene expression and assess 
specific molecular pathways that contribute to restenosis and thrombosis.  
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APPENDIX 
Aortic Endothelial Denudation Protocol 
 
 
23 
 
 
  
24 
 
Evans Blue & Perfusion Fixation Protocol 
 
 
 Photographs of Procedure
 
Figure 9 – Assembled Injury Catheter. 
I.U./mL. 
 
Figure 10 – Femoral Artery Catheterization.
advancement into the abdominal aorta.
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Preparation of injury catheter with heparinized saline 100 
 Successful catheterization of the injury catheter bef
 
 
 
ore 
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Figure 11 – Evans Blue Injection. 50 µ L of 40 mg/mL of Evans Blue delivered directly into the blood 
with 100 I.U./mL heparinized saline through the injury catheter. 
 
 Figure 12 – After a Perfusion Fixation Protocol.
PFA/PBS and removal of blood 
Left hind paw not stained blue d
stained indicates circulation of dye throughout extremities
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 (1) - Clear liver indicates successful perfusion of 
(2) - Blue stained intestine indicates perfusion of Evans blue dye 
ue to ligation distal to insertion site (no blood flow) (4) 
 
 
4% 
(3) - 
- Right hind paw 
